Ruboxistaurin results: Eli Lilly plans more trials

February 1, 2003

Indianapolis-Eli Lilly and Co. will delay the submission of its ruboxistaurin for the treatment of diabetic retinopathy and diabetic macular edema (DME) after two clinical trials failed to achieve satisfactory results on disease progression.